US › Healthcare

Relmada Therapeutics Inc (RLMD)

US · Healthcare · Biotechnology

$5.47+3.21%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-19.1M
Profit YoY
-8.5%
EPS
$-0.22
EPS estimate
$-0.20

EPS came in at -0.22 against a street estimate of -0.20 — a miss of 12.8%.

Key statistics

Market cap
$557.5M
Forward P/E
0.0
P/B
2.55
Book value
$10.15
EPS (TTM)
$-1.09
52-week high
$8.00
52-week low
$0.55
50-day MA
$6.27
200-day MA
$5.21
Beta
0.83

Analyst view

Analysts rate Relmada Therapeutics Inc a hold (0 buy, 3 hold, 0 sell out of 3) with an average price target of $12.67.

Shareholding

Insiders
2.90%
Institutions
85.09%

Largest institutional holders

FundStake
HHG PLC10.54%
Squadron Capital Management LLC8.07%
Spruce Street Capital LP5.96%
VR Adviser, LLC4.61%
Adage Capital Partners Gp LLC4.54%
Orbimed Advisors, LLC4.49%
Marshall Wace Asset Management Ltd4.27%
Millennium Management LLC3.72%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Relmada Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.